We conducted a systematic review with meta-analysis of randomized controlled trials that evaluated the effect of diabetes mobile phone applications. A total of 1550 participants from 21 studies were included. For type 1 diabetes, a significant 0.49% reduction in HbA1c was seen (95% CI, 0.04-0.94; I 2 = 84%), with unexplained heterogeneity and a low GRADE of evidence.
We conducted a systematic review with meta-analysis of randomized controlled trials that evaluated the effect of diabetes mobile phone applications. A total of 1550 participants from 21 studies were included. For type 1 diabetes, a significant 0.49% reduction in HbA1c was seen (95% CI, 0.04-0.94; I 2 = 84%), with unexplained heterogeneity and a low GRADE of evidence.
For type 2 diabetes, using diabetes apps was associated with a mean reduction of 0.57% (95% CI, 0.32-0.82; I 2 = 77%). The results had severe heterogeneity that was explained by the frequency of HCP feedback. In studies with no HCP feedback, low frequency and high frequency HCP feedback, the mean reduction is 0.24% (95% CI, 0.02-0.49; I 2 = 0%), 0.33% (95% CI, 0.07-0.59; I 2 = 47%) and 1.12% (95% CI, 0.91-1.32; I 2 = 0%), respectively, with a high GRADE of evidence. There is evidence that diabetes apps improve glycaemic control in type 1 diabetes patients. A reduction of 0.57% in HbA1c was found in type 2 diabetes patients. However, HCP functionality is important to achieve clinical effectiveness. Future studies are needed to explore the cost-effectiveness of diabetes apps and the optimal intensity of HCP feedback. Table S1 for search strategies and screening criteria). For data extraction, participant demographics, study design considerations and context were extracted from each included study (Tables S2 and S3 ). Corresponding authors were contacted to provide missing data and, where necessary, we used statistical methods to impute missing data (Table S2) We used the inverse variance random effects model 4 to pool mean differences (MD) in HbA1c changes from baseline or postintervention HbA1c for T1D and T2D studies separately. Subgroup analyses by HCP intensity were carried out for both T1D and T2D studies to explain heterogeneity. Random-effects meta-regressions were carried out for T2D studies to explore the factors that may influence the efficacy of diabetes apps on glycaemic control. Sensitivity analyses were carried out by removing studies with a high Risk of Bias (RoB), studies that had missing data imputation, and studies conducted with mixed participants. When 10 or more studies were pooled, we used funnel plot to visually inspect publication bias. All statistical analyses were conducted using STATA (version 14.1) and
Comprehensive Meta-Analysis (version 3).
| RESULTS
A total of 21 studies (Table S4) were identified from 7433 records ( Figure S1 ), among which 14 studies conceerned T2D, 5 studies concerned T1D and 2 studies, concerning both, were included in both T1D and T2D syntheses. The median follow-up period was 6 months (range, 3-9 months) and 6 months (range, 1.5-12 months) in T1D and T2D studies, respectively.
One T1D study and 3 T2D studies were at a high RoB, because of the absence of blinding, use of fixed permuted-block randomization in open-label trials, and high loss to follow-up. The risk of bias in the remaining studies was unclear ( Figures S2 and S3 ).
A total of 19 diabetes apps were assessed (Table S3) . Among T1D apps, 2 diabetes apps aimed to help patients with insulin bolus calculation and the others were designed to improve self-management by providing automated feedback or HCP feedback. As for HCP feedback, it was provided in 4 apps, with the frequency ranging from once weekly to once monthly. In contrast, the majority of T2D apps were designed to support diabetes self-management by providing personalized feedback on self-monitoring data. In terms of HCP feedback, 4 studies of diabetes apps had no HCP feedback. In the remaining 12 studies of diabetes apps, 7 provided low-frequency HCP feedback and (when necessary or ≦ once monthly) 5 had high-frequency HCP feedback (> once per month).
After pooling of T1D studies, we found a mean reduction of 0.49% in HbA1c that favoured the intervention (95% CI, 0.04-0.94; P = .03) (Figure 1 ), but considerable heterogeneity was exhibited (I 2 = 84%), which was partially explained by HCP feedback. We conducted 2 sensitivity analyses. Removing 1 study with incomplete data reported an insignificant reduction of 0.49% (95%CI, −0.04 to 1.01).
When 1 study with high RoB was removed, the mean reduction decreased to 0.35% (95% CI, −0.11 to 0.81). The level of evidence by GRADE was low, downgraded because of blinding and imprecision.
For T2D, the pooled results indicated that, compared with control, using diabetes apps was associated with a mean reduction of 0.57% in HbA1c (95% CI, 0.32-0.82; P < .01) (Figure 2 ). Although these results exhibited heterogeneity (I 2 = 77%), this was explained by the HCP intensity. Studies with no HCP feedback reported a mean reduction of 0.24% (95% CI, −0.02 to 0.49), whereas this increased in studies with low and high feedback, to 0.33% (95% CI, 0.07-0.59) and 1.12% (95% CI, 0.91-1.32), respectively. The level of evidence by GRADE for diabetes apps was high, based on downgrading for blinding, but upgrading for dose-response.
Three sensitivity analyses were planned, because of poor quality and a low completion rate; neither impacted on the interpretation of our findings. There is no indication of publication bias in Figure S4 .
Although 7 studies included severe hypoglycaemic episodes, these were infrequently reported and our findings are inconclusive. A planned meta-regression further explored the heterogeneity ( Figures S5-S7 ).
| DISCUSSION
This systematic review updated the body of evidence of diabetes apps to improve glycaemic control in the self-management of diabetes. For T1D, a statistically significant reduction in HbA1c that favored the use of diabetes apps is reported for the first time. The results reaffirmed that apps for T2D help with self-management, but also demonstrated a HCP dose-response with HbA1c.
The strengths of our meta-analysis are strict and follow a registered protocol, separating T1D and T2D patients and the use of a meta-regression method for controlling potential confounders.
Nevertheless, our study has some limitations. Firstly, we restricted the review to published articles, which may have introduced publication bias. Secondly, the issue of high risk of ascertainment bias existed in all the included studies. Meanwhile, the assessment of risk of bias of included studies was inadequate for some domains.
Finally, because of insufficient numbers of studies, we were not able to investigate interactions between different functionalities of the diabetes apps.
Although the results in T2D were associated with significant heterogeneity, it was significantly decreased after we stratified the studies by HCP intensity. The results from univariate meta-regressions suggested that baseline HbA1c levels were a significant mediator for the effect of diabetes apps. The positive association between baseline HbA1c levels and reductions in HbA1c is anticipated and accordant with findings in other diabetes research studies, 5, 6 as patients with higher baseline HbA1c levels generally have poorer glycaemic control and are therefore more likely to benefit from interventions. The inverse linear relationship between mean ages of the participants and reductions in HbA1c agrees with our previous hypothesis that younger patients were more likely to benefit from the use of diabetes apps. 1 As older patients were less interested in the use of diabetes apps, 7 it is plausible that diabetes apps are less effective among older patients. However, future studies are needed to investigate this relationship more deeply. Our results suggest no association with duration of follow-up, and this finding is supported by other studies. 8, 9 However, whether the effect of diabetes apps can be sustained for a longer period of time (>1 year) remains largely unknown.
Results from subgroup analyses and meta-regression present a clear dose-response, in studies of apps with a more intense HPC involvement, patients exhibited greater glycemic control. Among the 4 studies with high HCP intensity, all of them provided medication adjustment support. In the 8 studies with low HCP intensity, In the 8 studies with low HCP intensity, HCP were able to offer medication adjustment in less than half of the studies medication adjustment HCPs was included in less than half of the studies.
Our speculation is consistent with the findings of previous metaanalyses that investigated other diabetes telemedicine interventions and diabetes quality improvement strategies. 6,11 Therefore, we believe that it is medication adjustment support that plays a crucial role in the effect of HCP feedback. Based on these results, we postulate 2 main mechanisms behind the effects of diabetes apps on HbA1c reduction ( Figure S8 ).
For studies on T1D, although we found a statistically significant reduction in 0.49%, the result had some heterogeneity, and the current level of evidence was rated as low by GRADE, meaning that future research is likely to change the estimate.
Although there is some indication that the use of diabetes apps is not associated with an excess of severe episodes of hypoglycaemia, current evidence concerning the safety of diabetes apps is scarce.
Thus, future studies concerning diabetes apps should direct more attentions to safety issues, especially for apps with bolus calculator functionality.
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The population-wide implementation of diabetes apps requires the support of both clinicians and those financially responsible. For clinicians, the primary consideration is not only the clinical effect of using diabetes apps but, more importantly, whether the time spent to adapt the technology and send feedback justifies the perceived benefit. 13 Hence, the type and intensity of HCP feedback should be evaluated and reported in future research. We suggest that, in the future, diabetes management should be underpinned by behavioral principles and self-management guidelines, and should incorporate gamification elements 14 and a social medial function. 7 Future investigators should consider conducting a comprehensive economic evaluation that takes into account both the direct and indirect cost of diabetes apps. Meanwhile, investigators should direct more attention to evaluating the safety of diabetes apps. The long-term effects (>1 year) of diabetes apps are still unknown and need to be investigated in more pragmatic observational studies. 
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